Value Adjusted for Debt and Cash: Nasus Pharma (NSRX)

Brandmark of Nasus Pharma (NSRX)

The current share price of Nasus Pharma Ltd (NSRX) shown on this chart is 33.38, which correlates with its strategy of developing nasal sprays for antiviral protection and emergency therapy. The Israeli biotech firm is expanding its network of regional suppliers in Asia, avoiding mergers due to a shortage of funds. The business's success depends on regulatory approvals and the efficacy of drug delivery systems for acute conditions.

nasuspharma.com (NSRX) - Total Company Value from 12/30/2025 to 10/30/2026

Summary analytical data breakdowns for Nasus Pharma (NSRX)

- stock value and consensus price forecast:
Market Chart Nasus Pharma Ltd.|NSRX - Price Target Chart
- company stock exchange capitalization indicators:
Market Value Nasus Pharma|NSRX - Real Price to Acquire Entire Company
- book capitalization information:
Equity per Share Nasus Pharma|NSRX - Company Book Value|Capitalization to Book Value Ratio nasuspharma.com|NSRX - Company Total Assets
- company total debt and liquidity indicators:
Total Debt to Capital Nasus Pharma Ltd|NSRX - Long-Term Debt to Equity|Ratio of Short-Term Indebtedness to Capital Nasus Pharma Ltd.|NSRX - Company Aggregate Debts|Debt to Book Value Nasus Pharma|NSRX - Company Long-Term Debt|Short-Term Debt Nasus Pharma|Intermediate Coverage Ratio nasuspharma.com
- earnings and valuation multiples indicators:
NSRX - Net Profit
Summary company analytics:NSRX - Nasus Pharma Ltd
Original product of Nasus Pharma, Ltd.

Enterprise Value (EV) sums market capitalization and net debt, determining the total acquisition price of a business. This metric is sensitive to changes in debt load and liquidity balances within financial statements. By analyzing the structure and dynamics of EV, an investor assesses the real value of assets. For Nasus Pharma Ltd (NSRX), this indicator reflects financial stability in the face of logistical disruptions. Geopolitical instability in supply chains can directly impact the company's market valuation.

Competitors of Nasus Pharma Ltd (NSRX)

Company Buyout Price Indivior plc (INDV)|COLL - Total Company Value|Value Adjusted for Debt and Cash CRON (Cronos Corp)|CGC (Canopy Growth) - Real Price to Acquire Entire Company|Business Value HITI|Total Company Value Aurora Cannabis, Inc.|Business Value ACHV (Achieve Life Sciences Inc.)|Enterprise Value SKYE|Enterprise Value Anebulo Pharma (ANEB)|Total Company Value InterCure INCR|Value Adjusted for Debt and Cash NTRB|IGC Pharma Inc - Enterprise Value|MIRA Pharmaceuticals (MIRA) - Real Price to Acquire Entire Company|Flora Growth Corporation (FLGC) - Total Company Value|Total Enterprise Value IM Cannabis (IMCC)|Real Price to Acquire Entire Company ADIL|ARTL: Value Adjusted for Debt and Cash|Enterprise Value ENSC|TTNP: Full Business Value|Enterprise Value GNLN (Greenlane Holdings Inc)|Enterprise Value InMed INM|AKAN - Total Company Value|Value Adjusted for Debt and Cash ENVB (enveric.com)|brightgreen.us (BGXX) - Total Company Value|Real Price to Acquire Entire Company Hempacco Co Inc.